Lv3
330 积分 2023-02-27 加入
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)
4天前
已完结
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)
4天前
已关闭
BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)
4天前
已关闭
Top companies and drugs by sales in 2023
9个月前
已完结
Nucleolar URB1 ensures 3′ ETS rRNA removal to prevent exosome surveillance
11个月前
已完结
Emerging roles of nuclear bodies in genome spatial organization
11个月前
已完结
Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis
1年前
已完结
Gene Therapy Repairs for the Epileptic Brain: Potential for Treatment and Future Directions
1年前
已完结
PI3Kβ controls immune evasion in PTEN-deficient breast tumours
1年前
已完结
Retrograde Parotid Gland Infusion through Stensen's Duct in a Non-Human Primate for Vectored Gene Delivery
1年前
已完结
皖公网安备34019202002308
